CARLSBAD, Calif.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has granted approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic (CDx) to aid in ...
Thermo Fisher Scientific Inc. TMO recently announced the receipt of the FDA premarket approval (PMA) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to help identify epidermal growth ...
Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer generates results in as little as 24 hours to support timely therapy decisions A patient’s tumor profile has the potential ...
The FDA approved the Oncomine Dx Target Test for identifying HER2-mutant NSCLC patients eligible for Hernexeos, an oral tyrosine kinase inhibitor. Hernexeos offers a new treatment option for ...
The FDA approved the Oncomine Dx Express Test for rapid identification of NSCLC patients eligible for Zegfrovy treatment. The test provides results in 24 hours, aiding timely therapeutic decisions and ...
The circulating T-cell receptor (TCR) repertoire is a dynamic representation of overall immune responses in an individual. Here we aimed to correlate pre-treatment circulating TCR repertoire metrics ...
Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration (“FDA”) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results